Liquidia Corporation Common Stock vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Liquidia Corporation Common Stock trades at $34 (market cap $3.04B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.8 (market cap $7.97B). The key difference: Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is far larger — about 2.6× Liquidia Corporation Common Stock's market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| LQDA | PDBC | |
|---|---|---|
Market Cap | $3.04B | $7.97B |
Volume | 21,111,778 | 3,246,731 |
Sector | Health | — |
52-Week High | $91.03 | $20.10 |
52-Week Low | $22.02 | $13.19 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $2.94B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $19.98, up 0.6% on the day, with a strong bullish technical signal from moving averages. The ETF has delivered robust performance, rising 45.66% year-to-date through Q3 2026, driven by gains in energy and agricultural commodities amid geopolitical tensions. Institutional interest is growing, with several advisors increasing positions recently, though short interest also surged significantly in September.
The outlook for PDBC remains positive given ongoing commodity strength and defensive investor shifts, but risks include heightened short interest and geopolitical volatility that could pressure returns. Investors should weigh the ETF's momentum against potential pullbacks from overbought conditions and external shocks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →